Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 9.7% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics Inc. (NTLA) specializes in developing CRISPR-based gene editing therapies. Today, the stock experienced a notable bearish trend.

Why is Intellia Therapeutics, Inc. going down?

NTLA stock is down 9.7% on Jun 5, 2026 17:12

• Expectations and optimism preceding the Phase 3 results of the lonvo-z study for hereditary angioedema (HAE) likely drove a significant price surge before the announcement.
• Despite initial positivity and strong performance in gene-editing technology, the market response to the actual Phase 3 results may have been negative, potentially falling below expectations.
• Conflicting viewpoints on the company's valuation, with some suggesting it is undervalued while market comparisons suggest a higher price compared to industry peers, could have prompted profit-taking and the bearish movement in the stock price.
• Investors may be reassessing their positions and weighing the potential risks and rewards linked to Intellia Therapeutics, resulting in a sell-off and the bearish movement witnessed today.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Intellia (NTLA) Rockets 13% Ahead of Phase 3 Lonvo-Z Study Update

Intellia Therapeutics Inc. (NTLA) saw its stock price jump 13.29% ahead of the Phase 3 results of its Lonvo-z study for hereditary angioedema (HAE). The company announced it would present these late-breaking results at the EAACI Annual Congress 2026. Lonvo-z is an experimental gene-editing therapy aiming to be a one-time functional cure for HAE, and if approved, would be the world’s first in vivo CRISPR-based gene editing therapy.

https://uk.finance.yahoo.com/news/intellia-ntla-rockets-13-ahead-012316479.html

Intellia (NTLA) Rockets 13% Ahead of Phase 3 Lonvo-Z Study Update

Intellia Therapeutics Inc. (NASDAQ:NTLA) saw its shares jump 13.29% as investors anticipate the phase 3 results of its lonvo-z study for hereditary angioedema (HAE). The company is set to present the late-breaking results at the EAACI Annual Congress 2026 in Istanbul and has already submitted a biologics license application for lonvo-z, which aims to be the world's first in vivo CRISPR-based gene editing therapy.

https://www.insidermonkey.com/blog/intellia-ntla-rockets-13-ahead-of-phase-3-lonvo-z-study-update-1775237/?amp=1

NTLA Stock Climbs As Phase 3 Wins Meet Extended Cash Runway

Intellia Therapeutics Inc. (NTLA) stock surged by 13.94% due to positive Phase 3 CRISPR gene-editing trial results and extended cash runway. The company's Q1 2026 revenue beat expectations, and its lead candidate, lonvoguran ziclumeran, shows a clear path to market, aiming for a U.S. launch in early 2027. Despite a dilutive equity raise, analyst ratings remain largely positive, and ARK Investment's recent purchase signifies renewed institutional interest.

https://stockstotrade.com/news/intellia-therapeutics-inc-ntla-news-2026_06_04/

A Look At Intellia Therapeutics (NTLA) Valuation As Phase 3 HAELO Gene Editing Data Approaches

Intellia Therapeutics (NTLA) is gaining investor attention as it approaches the release of Phase 3 HAELO trial data for its gene-editing therapy in hereditary angioedema. Despite strong short-term stock performance and a perceived undervaluation by some analysts, the company's high P/S ratio compared to industry averages suggests that a significant amount of future growth may already be priced in, leading to mixed signals on its current valuation. Investors are encouraged to review the data, considering both potential rewards and warning signs, and to broaden their watchlist beyond a single stock.

https://www.sahmcapital.com/news/content/a-look-at-intellia-therapeutics-ntla-valuation-as-phase-3-haelo-gene-editing-data-approaches-2026-06-02

A Look At Intellia Therapeutics (NTLA) Valuation As Phase 3 HAELO Gene Editing Data Approaches

Intellia Therapeutics (NTLA) is drawing investor attention as it prepares to present Phase 3 HAELO trial data for its gene-editing therapy, lonvo-z. Despite significant share price gains over the past year, the company's valuation presents mixed signals, with some analysts suggesting it is undervalued while market multiples indicate a high price relative to peers. Investors are urged to examine key risks and varied analyses to determine the true buying opportunity.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/a-look-at-intellia-therapeutics-ntla-valuation-as-phase-3-ha/amp

Trending Today

Bitcoin ($BTC) Crypto Forecast: Down 5.1% Today

ZCash ($ZEC) Crypto Forecast: Down 16.7% Today

Ethereum ($ETH) Crypto Forecast: Down 11.1% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 6.7% Today

Diamondback Energy Inc. ($FANG) Stock Forecast: Down 5.0% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 16.7% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Down 11.5% Today

Newmont Mining Corporation ($NEM) Stock Forecast: Down 7.5% Today

Halliburton Company ($HAL) Stock Forecast: Down 5.4% Today

Baker Hughes Company ($BKR) Stock Forecast: Down 5.0% Today

Intellia Therapeutics, Inc. Price History

01.05.2026 - NTLA Stock was up 5.4%

• NTLA-2001, Intellia's CRISPR-based treatment for ATTR amyloidosis with cardiomyopathy, successfully met the primary endpoint in a pivotal Phase 3 trial. This positive outcome, showing a significant reduction in mortality and cardiovascular events, has fueled investor optimism and confidence in the company's gene editing therapies.
• The FDA lifting clinical holds on Intellia's candidates, lonvoguran ziclumeran and nexiguran ziclumeran, further contributed to the stock's surge. These regulatory advancements signal progress towards potential commercialization and alleviate uncertainties surrounding the company's in vivo CRISPR programs.
• Despite the positive developments, the need for ongoing clinical success and timely FDA approvals to manage cash burn was highlighted by the company's reliance on equity offerings for funding. This underscores the importance of continued regulatory milestones and successful trial outcomes for sustaining investor interest and financial stability in the future.

05.05.2026 - NTLA Stock was down 6.9%

• The bearish movement in NTLA stock today could be attributed to profit-taking by investors after the significant surge in stock price following positive Phase 3 trial results and extended cash runway.
• Despite the positive sentiment surrounding the Phase 3 trial results and analyst ratings, the mixed signals on the company's valuation, with some suggesting it is already priced for future growth, might have caused caution among investors.
• The anticipation around the upcoming Phase 3 HAELO trial data release for lonvo-z therapy could have led to heightened volatility and uncertainty in the stock price, prompting some investors to take a step back and reassess their positions.
• The discrepancy between the perceived undervaluation by some analysts and the high price relative to peers based on market multiples may have created a sense of ambiguity among investors, contributing to the bearish movement in NTLA stock today.

18.04.2026 - NTLA Stock was down 5.7%

• The recent bearish movement in NTLA stock could be linked to negative insider sentiment, with an increase in share sales by corporate insiders over the past quarter, as noted by a Hold rating and $12.00 price target.
• Despite positive Phase 3 results for lonvo-z and progress on its biologics license application, mixed short-term share price performance and diverse views from analysts may have contributed to the downward pressure on the stock.
• The wide spread in analyst valuations, hinting at uncertainty about the company's growth potential, could have also influenced investors to take a cautious stance, resulting in the bearish movement in NTLA stock.
• In general, while the company's clinical advancements and financial strategy are respected, lingering concerns about valuation and differing views on future growth prospects appear to have impacted the stock performance.

05.05.2026 - NTLA Stock was down 9.7%

• Expectations and optimism preceding the Phase 3 results of the lonvo-z study for hereditary angioedema (HAE) likely drove a significant price surge before the announcement.
• Despite initial positivity and strong performance in gene-editing technology, the market response to the actual Phase 3 results may have been negative, potentially falling below expectations.
• Conflicting viewpoints on the company's valuation, with some suggesting it is undervalued while market comparisons suggest a higher price compared to industry peers, could have prompted profit-taking and the bearish movement in the stock price.
• Investors may be reassessing their positions and weighing the potential risks and rewards linked to Intellia Therapeutics, resulting in a sell-off and the bearish movement witnessed today.

14.04.2026 - NTLA Stock was down 9.8%

• Despite a reduced loss per share in Q1 2026, Intellia Therapeutics (NTLA) witnessed a decline in the market today.
• The company outperformed in earnings but fell short of revenue expectations, potentially influencing negative investor reactions.
• Analysts hold varying perspectives on the company's future, citing worries about sustained losses and the path to profitability that could have impacted the stock price.
• Negative insider sentiment and larger-than-anticipated losses per share in the recent quarter may have contributed to the stock's downturn, notwithstanding optimistic pipeline developments.

14.04.2026 - NTLA Stock was down 5.8%

• NTLA posted a Q1 2026 net loss of $96.2 million, which has sparked worries about its path to profitability and prompted a cautious response from investors.
• While exceeding earnings per share projections, the company fell short on revenue, reporting $15 million, leading to a downward trend in the market.
• The persistent losses, high price-to-sales ratio, and risks of dilution may have contributed to the prevailing bearish sentiment and decline in NTLA shares.
• Despite positive developments in its pipeline, such as successful Phase 3 outcomes for lonvo-z and the lifting of FDA clinical holds for nex-z trials, concerns about financial performance and short-term profitability seem to overshadow these advancements.

19.04.2026 - NTLA Stock was down 8.3%

• The recent bearish movement in NTLA's stock may be linked to investor concerns about potential dilution following a recent $180 million equity offering, despite an improved net loss reported in Q1 2026.
• Investors are wary of the possibility of further dilution if current cash burn rates persist, despite Intellia Therapeutics' affirmation of a multi-year cash runway and positive developments in its gene-editing pipeline.
• Market sentiment seems influenced by uncertainties surrounding future funding requirements and the trade-off between benefits from capital raising and risks of dilution, as suggested in recent discussions on the company's valuation and financial performance.
• Despite encouraging results from clinical trials and advancements in regulatory milestones, today's downward movement in the stock price may reflect a broader market reassessment of Intellia Therapeutics' growth prospects and valuation, resulting in a temporary decline in share value.

02.05.2026 - NTLA Stock was down 5.3%

• The bearish movement in NTLA stock could be attributed to profit-taking by investors after a recent bullish run following positive Phase III results for lonvoguran ziclumeran and the successful pivotal trial for NTLA-2001.
• Despite the positive news, investors may have been concerned about the company's reliance on equity offerings to fund development, leading to a cautious sentiment in the market.
• The market may also be reacting to potential uncertainties surrounding the commercialization timeline of Intellia's CRISPR therapies, as regulatory approvals and clinical success remain crucial factors for the company's growth trajectory.

02.05.2026 - NTLA Stock was down 7.1%

• The bearish movement in NTLA's stock price today could be attributed to profit-taking by investors after a recent surge in the stock following positive Phase III trial results for its CRISPR-based therapy, lonvoguran ziclumeran.
• Despite the successful pivotal trial results for NTLA-2001 in treating ATTR amyloidosis with cardiomyopathy, the market may have reacted negatively due to concerns about the company's ongoing need for equity offerings to fund development, indicating potential dilution for existing shareholders.
• The undervaluation of NTLA highlighted by analysts, despite positive developments, might have also contributed to the bearish sentiment as investors may be cautious about the company's ability to secure strong payer support for expensive gene editing treatments in the future.
• Overall, the market movement in NTLA today reflects a mix of profit-taking, concerns about funding strategies, and uncertainties surrounding the commercialization and market acceptance of its CRISPR-based therapies.

27.04.2026 - NTLA Stock was up 8.2%

• NTLA reported a reduced first-quarter loss, demonstrating improved financial performance compared to the prior year. This improvement has likely contributed to the positive movement in the stock.
• Positive Phase 3 clinical data for lonvo-z in Hereditary Angioedema (HAE) and advancements in other trials have enhanced investor confidence in the company's future prospects, leading to increased interest and a favorable market sentiment.
• Analysts have set a fair value target of $26.70 for the company, suggesting potential undervaluation. This, along with the anticipation of new product launches and a strengthened financial position, likely plays a role in the stock's upward momentum.
• The resolution of the patent infringement lawsuit counterclaims signals the end of legal uncertainties, potentially eliminating a source of concern for investors and further supporting the stock's positive trajectory.

22.04.2026 - NTLA Stock was up 5.6%

• The dismissal of four counterclaims in the BlueAllele patent infringement lawsuit is seen as a positive development for Intellia Therapeutics, reducing legal uncertainties and potential financial liabilities.
• The submission of the CRISPR-based gene editing therapy, nex-z, poses a unique regulatory challenge for the FDA, highlighting the innovative nature of Intellia's technology and its potential market impact.
• Despite concerns about dilution from a recent equity offering, Intellia's improved net loss in Q1 2026 and emphasis on a multi-year cash runway are reassuring investors about the company's financial stability and ability to execute its gene-editing pipeline.
• Investor focus on Intellia's gene-editing pipeline progress, upcoming clinical trial readouts, and regulatory milestones underscores the market's anticipation of potential breakthroughs in the competitive gene-editing landscape, further boosting confidence in the company's growth prospects.

04.05.2026 - NTLA Stock was up 18.0%

• NTLA stock surged due to the successful results of its CRISPR-based treatment, NTLA-2001, in a pivotal Phase 3 trial for ATTR amyloidosis with cardiomyopathy, demonstrating a significant reduction in mortality and cardiovascular events.
• The positive Phase III results for its CRISPR therapy, lonvoguran ziclumeran, and the FDA lifting clinical holds on another candidate, nexiguran ziclumeran, also contributed to the stock's rise.
• Analysts view NTLA as undervalued, presenting a potential buying opportunity as the company prepares to release Phase 3 HAELO trial data for lonvo-z, its gene-editing therapy for hereditary angioedema.
• The company's success in advancing its gene-editing therapies towards potential commercialization, alongside ongoing clinical achievements, has boosted investor confidence in NTLA's future prospects, driving the bullish market movement.